Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
Int J Hematol. 2023 Aug 15. doi: 10.1007/s12185-023-03646-3. Online ahead of print.NO ABSTRACTPMID:37581752 | DOI:10.1007/s12185-023-03646-3 (Source: International Journal of Hematology)
Source: International Journal of Hematology - August 15, 2023 Category: Hematology Authors: Koji Izutsu Kazuhito Yamamoto Koji Kato Takayuki Ishikawa Noriko Fukuhara Yasuhito Terui Ilseung Choi Sumiko Okubo Natsumi Ogawa Mizu Sakai Yasuko Nishimura Brenda Chyla Yan Sun Dai Maruyama Source Type: research

Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
Int J Hematol. 2023 Aug 15. doi: 10.1007/s12185-023-03646-3. Online ahead of print.NO ABSTRACTPMID:37581752 | DOI:10.1007/s12185-023-03646-3 (Source: International Journal of Hematology)
Source: International Journal of Hematology - August 15, 2023 Category: Hematology Authors: Koji Izutsu Kazuhito Yamamoto Koji Kato Takayuki Ishikawa Noriko Fukuhara Yasuhito Terui Ilseung Choi Sumiko Okubo Natsumi Ogawa Mizu Sakai Yasuko Nishimura Brenda Chyla Yan Sun Dai Maruyama Source Type: research

Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
Int J Hematol. 2023 Aug 15. doi: 10.1007/s12185-023-03646-3. Online ahead of print.NO ABSTRACTPMID:37581752 | DOI:10.1007/s12185-023-03646-3 (Source: International Journal of Hematology)
Source: International Journal of Hematology - August 15, 2023 Category: Hematology Authors: Koji Izutsu Kazuhito Yamamoto Koji Kato Takayuki Ishikawa Noriko Fukuhara Yasuhito Terui Ilseung Choi Sumiko Okubo Natsumi Ogawa Mizu Sakai Yasuko Nishimura Brenda Chyla Yan Sun Dai Maruyama Source Type: research

Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
Int J Hematol. 2023 Aug 15. doi: 10.1007/s12185-023-03646-3. Online ahead of print.NO ABSTRACTPMID:37581752 | DOI:10.1007/s12185-023-03646-3 (Source: International Journal of Hematology)
Source: International Journal of Hematology - August 15, 2023 Category: Hematology Authors: Koji Izutsu Kazuhito Yamamoto Koji Kato Takayuki Ishikawa Noriko Fukuhara Yasuhito Terui Ilseung Choi Sumiko Okubo Natsumi Ogawa Mizu Sakai Yasuko Nishimura Brenda Chyla Yan Sun Dai Maruyama Source Type: research

Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
Int J Hematol. 2023 Aug 15. doi: 10.1007/s12185-023-03646-3. Online ahead of print.NO ABSTRACTPMID:37581752 | DOI:10.1007/s12185-023-03646-3 (Source: International Journal of Hematology)
Source: International Journal of Hematology - August 15, 2023 Category: Hematology Authors: Koji Izutsu Kazuhito Yamamoto Koji Kato Takayuki Ishikawa Noriko Fukuhara Yasuhito Terui Ilseung Choi Sumiko Okubo Natsumi Ogawa Mizu Sakai Yasuko Nishimura Brenda Chyla Yan Sun Dai Maruyama Source Type: research

Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
Int J Hematol. 2023 Aug 15. doi: 10.1007/s12185-023-03646-3. Online ahead of print.NO ABSTRACTPMID:37581752 | DOI:10.1007/s12185-023-03646-3 (Source: International Journal of Hematology)
Source: International Journal of Hematology - August 15, 2023 Category: Hematology Authors: Koji Izutsu Kazuhito Yamamoto Koji Kato Takayuki Ishikawa Noriko Fukuhara Yasuhito Terui Ilseung Choi Sumiko Okubo Natsumi Ogawa Mizu Sakai Yasuko Nishimura Brenda Chyla Yan Sun Dai Maruyama Source Type: research

Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
Int J Hematol. 2023 Aug 15. doi: 10.1007/s12185-023-03646-3. Online ahead of print.NO ABSTRACTPMID:37581752 | DOI:10.1007/s12185-023-03646-3 (Source: International Journal of Hematology)
Source: International Journal of Hematology - August 15, 2023 Category: Hematology Authors: Koji Izutsu Kazuhito Yamamoto Koji Kato Takayuki Ishikawa Noriko Fukuhara Yasuhito Terui Ilseung Choi Sumiko Okubo Natsumi Ogawa Mizu Sakai Yasuko Nishimura Brenda Chyla Yan Sun Dai Maruyama Source Type: research

Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
Int J Hematol. 2023 Aug 15. doi: 10.1007/s12185-023-03646-3. Online ahead of print.NO ABSTRACTPMID:37581752 | DOI:10.1007/s12185-023-03646-3 (Source: International Journal of Hematology)
Source: International Journal of Hematology - August 15, 2023 Category: Hematology Authors: Koji Izutsu Kazuhito Yamamoto Koji Kato Takayuki Ishikawa Noriko Fukuhara Yasuhito Terui Ilseung Choi Sumiko Okubo Natsumi Ogawa Mizu Sakai Yasuko Nishimura Brenda Chyla Yan Sun Dai Maruyama Source Type: research

Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
Int J Hematol. 2023 Aug 15. doi: 10.1007/s12185-023-03646-3. Online ahead of print.NO ABSTRACTPMID:37581752 | DOI:10.1007/s12185-023-03646-3 (Source: International Journal of Hematology)
Source: International Journal of Hematology - August 15, 2023 Category: Hematology Authors: Koji Izutsu Kazuhito Yamamoto Koji Kato Takayuki Ishikawa Noriko Fukuhara Yasuhito Terui Ilseung Choi Sumiko Okubo Natsumi Ogawa Mizu Sakai Yasuko Nishimura Brenda Chyla Yan Sun Dai Maruyama Source Type: research

Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
Int J Hematol. 2023 Aug 15. doi: 10.1007/s12185-023-03646-3. Online ahead of print.NO ABSTRACTPMID:37581752 | DOI:10.1007/s12185-023-03646-3 (Source: International Journal of Hematology)
Source: International Journal of Hematology - August 15, 2023 Category: Hematology Authors: Koji Izutsu Kazuhito Yamamoto Koji Kato Takayuki Ishikawa Noriko Fukuhara Yasuhito Terui Ilseung Choi Sumiko Okubo Natsumi Ogawa Mizu Sakai Yasuko Nishimura Brenda Chyla Yan Sun Dai Maruyama Source Type: research

Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
Int J Hematol. 2023 Aug 15. doi: 10.1007/s12185-023-03646-3. Online ahead of print.NO ABSTRACTPMID:37581752 | DOI:10.1007/s12185-023-03646-3 (Source: International Journal of Hematology)
Source: International Journal of Hematology - August 15, 2023 Category: Hematology Authors: Koji Izutsu Kazuhito Yamamoto Koji Kato Takayuki Ishikawa Noriko Fukuhara Yasuhito Terui Ilseung Choi Sumiko Okubo Natsumi Ogawa Mizu Sakai Yasuko Nishimura Brenda Chyla Yan Sun Dai Maruyama Source Type: research

Aortitis after administration of pegfilgrastim to a healthy donor for peripheral blood stem cell collection
Int J Hematol. 2023 Aug 14. doi: 10.1007/s12185-023-03649-0. Online ahead of print.ABSTRACTA 45-year-old man who was a sibling donor for allogeneic peripheral blood stem cell transplantation (allo-PBSCT) was administered 7.2 mg of pegfilgrastim for stem cell collection. Peripheral blood stem cells were collected 4 days after administration of pegfilgrastim (Day 4) and 4.32 × 106 /kg of CD34-positive cells per recipient body weight were obtained. Fever of 38 ℃ or higher and left submandibular pain appeared on Day 6. Ultrasonography and contrast-enhanced computed tomography (CT) showed wall thickening of the carotid arter...
Source: International Journal of Hematology - August 14, 2023 Category: Hematology Authors: Yu Uemura Kumi Oshima Aika Fuseya Akane Hosokai Ayaka Ohashi Masatoshi Kanno Ayako Arai Source Type: research

Antibody response after third dose of COVID-19 mRNA vaccination in allogeneic hematopoietic stem cell transplant recipients is comparable to that in healthy counterparts
Int J Hematol. 2023 Aug 10. doi: 10.1007/s12185-023-03648-1. Online ahead of print.ABSTRACTTo determine the efficacy of SARS-CoV-2 mRNA vaccination for allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients, we measured antibody titer serially in 92 allo-HSCT patients. Among the evaluable 87 patients, median age at vaccination was 53 years (range, 18-75). The average time between allo-HSCT and vaccination was 3.3 years (range, 0.5-15.7). One month after the second dose, 70 patients (80.5%) had a positive response, whereas 17 patients (19.5%) had a negative response (< 20 U/mL). Only patients older tha...
Source: International Journal of Hematology - August 10, 2023 Category: Hematology Authors: Erina Takagi Seitaro Terakura Hidetsugu Fujigaki Akinao Okamoto Kotaro Miyao Masashi Sawa Takanobu Morishita Tatsunori Goto Yukiyasu Ozawa Tetsuya Nishida Nobuaki Fukushima Kazutaka Ozeki Ryo Hanajiri Kuniaki Saito Makoto Murata Akihiro Tomita Hitoshi Kiy Source Type: research

Antibody response after third dose of COVID-19 mRNA vaccination in allogeneic hematopoietic stem cell transplant recipients is comparable to that in healthy counterparts
Int J Hematol. 2023 Aug 10. doi: 10.1007/s12185-023-03648-1. Online ahead of print.ABSTRACTTo determine the efficacy of SARS-CoV-2 mRNA vaccination for allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients, we measured antibody titer serially in 92 allo-HSCT patients. Among the evaluable 87 patients, median age at vaccination was 53 years (range, 18-75). The average time between allo-HSCT and vaccination was 3.3 years (range, 0.5-15.7). One month after the second dose, 70 patients (80.5%) had a positive response, whereas 17 patients (19.5%) had a negative response (< 20 U/mL). Only patients older tha...
Source: International Journal of Hematology - August 10, 2023 Category: Hematology Authors: Erina Takagi Seitaro Terakura Hidetsugu Fujigaki Akinao Okamoto Kotaro Miyao Masashi Sawa Takanobu Morishita Tatsunori Goto Yukiyasu Ozawa Tetsuya Nishida Nobuaki Fukushima Kazutaka Ozeki Ryo Hanajiri Kuniaki Saito Makoto Murata Akihiro Tomita Hitoshi Kiy Source Type: research

Antibody response after third dose of COVID-19 mRNA vaccination in allogeneic hematopoietic stem cell transplant recipients is comparable to that in healthy counterparts
Int J Hematol. 2023 Aug 10. doi: 10.1007/s12185-023-03648-1. Online ahead of print.ABSTRACTTo determine the efficacy of SARS-CoV-2 mRNA vaccination for allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients, we measured antibody titer serially in 92 allo-HSCT patients. Among the evaluable 87 patients, median age at vaccination was 53 years (range, 18-75). The average time between allo-HSCT and vaccination was 3.3 years (range, 0.5-15.7). One month after the second dose, 70 patients (80.5%) had a positive response, whereas 17 patients (19.5%) had a negative response (< 20 U/mL). Only patients older tha...
Source: International Journal of Hematology - August 10, 2023 Category: Hematology Authors: Erina Takagi Seitaro Terakura Hidetsugu Fujigaki Akinao Okamoto Kotaro Miyao Masashi Sawa Takanobu Morishita Tatsunori Goto Yukiyasu Ozawa Tetsuya Nishida Nobuaki Fukushima Kazutaka Ozeki Ryo Hanajiri Kuniaki Saito Makoto Murata Akihiro Tomita Hitoshi Kiy Source Type: research